Cargando…
A Secreted Form of the Hepatitis E Virus ORF2 Protein: Design Strategy, Antigenicity and Immunogenicity
Hepatitis E virus (HEV) is an important public health burden worldwide, causing approximately 20 million infections and 70,000 deaths annually. The viral capsid protein is encoded by open reading frame 2 (ORF2) of the HEV genome. Most ORF2 protein present in body fluids is the glycosylated secreted...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610824/ https://www.ncbi.nlm.nih.gov/pubmed/36298677 http://dx.doi.org/10.3390/v14102122 |
_version_ | 1784819373420052480 |
---|---|
author | Chen, Zihao Guo, Shaoqi Li, Guanghui Ying, Dong Wen, Guiping Fang, Mujin Wang, Yingbin Tang, Zimin Zheng, Zizheng Xia, Ningshao |
author_facet | Chen, Zihao Guo, Shaoqi Li, Guanghui Ying, Dong Wen, Guiping Fang, Mujin Wang, Yingbin Tang, Zimin Zheng, Zizheng Xia, Ningshao |
author_sort | Chen, Zihao |
collection | PubMed |
description | Hepatitis E virus (HEV) is an important public health burden worldwide, causing approximately 20 million infections and 70,000 deaths annually. The viral capsid protein is encoded by open reading frame 2 (ORF2) of the HEV genome. Most ORF2 protein present in body fluids is the glycosylated secreted form of the protein (ORF2(S)). A recent study suggested that ORF2(S) is not necessary for the HEV life cycle. A previously reported efficient HEV cell culture system can be used to understand the origin and life cycle of ORF2(S) but is not sufficient for functional research. A more rapid and productive method for yielding ORF2(S) could help to study its antigenicity and immunogenicity. In this study, the ORF2(S) (tPA) expression construct was designed as a candidate tool. A set of representative anti-HEV monoclonal antibodies was further used to map the functional antigenic sites in the candidates. ORF2(S) (tPA) was used to study antigenicity and immunogenicity. Indirect ELISA revealed that ORF2(S) (tPA) was not antigenically identical to HEV 239 antigen (p239). The ORF2(S)-specific antibodies were successfully induced in one-dose-vaccinated BALB/c mice. The ORF2(S)-specific antibody response was detected in plasma from HEV-infected patients. Recombinant ORF2(S) (tPA) can act as a decoy to against B cells. Altogether, our study presents a design strategy for ORF2(S) expression and indicates that ORF2(S) (tPA) can be used for functional and structural studies of the HEV life cycle. |
format | Online Article Text |
id | pubmed-9610824 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96108242022-10-28 A Secreted Form of the Hepatitis E Virus ORF2 Protein: Design Strategy, Antigenicity and Immunogenicity Chen, Zihao Guo, Shaoqi Li, Guanghui Ying, Dong Wen, Guiping Fang, Mujin Wang, Yingbin Tang, Zimin Zheng, Zizheng Xia, Ningshao Viruses Article Hepatitis E virus (HEV) is an important public health burden worldwide, causing approximately 20 million infections and 70,000 deaths annually. The viral capsid protein is encoded by open reading frame 2 (ORF2) of the HEV genome. Most ORF2 protein present in body fluids is the glycosylated secreted form of the protein (ORF2(S)). A recent study suggested that ORF2(S) is not necessary for the HEV life cycle. A previously reported efficient HEV cell culture system can be used to understand the origin and life cycle of ORF2(S) but is not sufficient for functional research. A more rapid and productive method for yielding ORF2(S) could help to study its antigenicity and immunogenicity. In this study, the ORF2(S) (tPA) expression construct was designed as a candidate tool. A set of representative anti-HEV monoclonal antibodies was further used to map the functional antigenic sites in the candidates. ORF2(S) (tPA) was used to study antigenicity and immunogenicity. Indirect ELISA revealed that ORF2(S) (tPA) was not antigenically identical to HEV 239 antigen (p239). The ORF2(S)-specific antibodies were successfully induced in one-dose-vaccinated BALB/c mice. The ORF2(S)-specific antibody response was detected in plasma from HEV-infected patients. Recombinant ORF2(S) (tPA) can act as a decoy to against B cells. Altogether, our study presents a design strategy for ORF2(S) expression and indicates that ORF2(S) (tPA) can be used for functional and structural studies of the HEV life cycle. MDPI 2022-09-26 /pmc/articles/PMC9610824/ /pubmed/36298677 http://dx.doi.org/10.3390/v14102122 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chen, Zihao Guo, Shaoqi Li, Guanghui Ying, Dong Wen, Guiping Fang, Mujin Wang, Yingbin Tang, Zimin Zheng, Zizheng Xia, Ningshao A Secreted Form of the Hepatitis E Virus ORF2 Protein: Design Strategy, Antigenicity and Immunogenicity |
title | A Secreted Form of the Hepatitis E Virus ORF2 Protein: Design Strategy, Antigenicity and Immunogenicity |
title_full | A Secreted Form of the Hepatitis E Virus ORF2 Protein: Design Strategy, Antigenicity and Immunogenicity |
title_fullStr | A Secreted Form of the Hepatitis E Virus ORF2 Protein: Design Strategy, Antigenicity and Immunogenicity |
title_full_unstemmed | A Secreted Form of the Hepatitis E Virus ORF2 Protein: Design Strategy, Antigenicity and Immunogenicity |
title_short | A Secreted Form of the Hepatitis E Virus ORF2 Protein: Design Strategy, Antigenicity and Immunogenicity |
title_sort | secreted form of the hepatitis e virus orf2 protein: design strategy, antigenicity and immunogenicity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610824/ https://www.ncbi.nlm.nih.gov/pubmed/36298677 http://dx.doi.org/10.3390/v14102122 |
work_keys_str_mv | AT chenzihao asecretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity AT guoshaoqi asecretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity AT liguanghui asecretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity AT yingdong asecretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity AT wenguiping asecretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity AT fangmujin asecretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity AT wangyingbin asecretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity AT tangzimin asecretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity AT zhengzizheng asecretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity AT xianingshao asecretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity AT chenzihao secretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity AT guoshaoqi secretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity AT liguanghui secretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity AT yingdong secretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity AT wenguiping secretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity AT fangmujin secretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity AT wangyingbin secretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity AT tangzimin secretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity AT zhengzizheng secretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity AT xianingshao secretedformofthehepatitisevirusorf2proteindesignstrategyantigenicityandimmunogenicity |